Cas no 16595-80-5 (Levamisole hydrochloride)
Levamisole hydrochloride Chemical and Physical Properties
Names and Identifiers
-
- (S)-6-Phenyl-2,3,5,6-tetrahydroimidazo[2,1-b]thiazole hydrochloride
- (-)-2,3,5,6-Tetrahydro-6-phenylimidazo[2,1-b]thiazole hydrochloride
- Tetramisole hydrochloride
- Levamisole HCL
- 1-b)thiazole,2,3,5,6-tetrahydro-6-phenyl-,monohydrochloride,(s)-imidazo(
- 1-b)thiazole,2,3,5,6-tetrahydro-6-phenyl-,monohydrochloride,l-(-)-imidazo(
- 1-b]thiazole,2,3,5,6-tetrahydro-6-phenyl-,monohydrochloride,(S)-Imidazo[2
- citarinl
- decaris
- Imidazo[2,1-b]thiazole,2,3,5,6-tetrahydro-6-phenyl-,monohydrochloride,(S)-
- kw-2-le-t
- L-2,3,5,6-Tetrahydro-6-phenylimidazo-[2,1-6]-thiazole
- Levamisole Hydrochloride
- Levamisol hydrochloride
- Levamisole Hydrochloride [for Biochemical Research]
- (-)-Tetramisole
- (-)-Tetramisole hydrochloride
- (?)-Levamisole hydrochloride solution
- Levamisole (hydrochloride)
- (-)-tetramisole HCl
- (-)-tetramisole*HCl
- Dekaris
- Levacide
- Levadin
- L-tetramisole hydrochloride
- r-12,564
- solaskil
- TRAMISOL
- tramisole
- (?)-2,3,5,6-Tetrahydro-6-phenylimidazo[2,1-b]thiazole hydrochloride
- L(?)-2,3,5,6-Tetrahydro-6-phenylimidazo(2,1-b)thiazole
- S(?)-6-Phenyl-2,3,5,6-tetrahydroimidazo[2,1-b]thiazole hydrochloride
- 鹽酸左旋咪唑原藥粉生產(chǎn)廠家行情價格
- Ergamisol
- Niratic hydrochloride
- Levasole
- Ascaridil
- Meglum
- Nilverm forte
- Worm-chek
- Stimamizol hydrochloride
- Ripercol-L
- Citarin L
- Niratic-puron hydrochloride
- Levomysol hydrochloride
- KW 2LE-T
- Spartakon
- Nemicide
- EI
- Le
- DTXSID7047518
- Tox21_500690
- NSC-177023
- R 12,564
- (-)-2,5,6-Tetrahydro-6-phenylimidazo[2,1-b]thiazole monohydrochloride
- CCG-40301
- NCGC00094446-03
- Levamisoli hydrochloridum
- LEVAMISOLE HYDROCHLORIDE [MI]
- Levamisole Hydrochloride (Ergamisol)
- Imidazo[2, 2,3,5,6-tetrahydro-6-phenyl-, monohydrochloride, (S)-
- 16595-80-5
- (S)-6-Phenyl-2,3,5,6-tetrahydroimidazo[2,1-b]thiazolehydrochloride
- Spartakon l
- CHEMBL1770
- Imidazo[2, 2,3,5,6-tetrahydro-6-phenyl-, monohydrochloride, (-)-
- HMS1922M11
- Tox21_111282
- Cloridrato de Levamizol
- HY-13666
- LEVAMISOLE HYDROCHLORIDE [ORANGE BOOK]
- J-521642
- Levasole Soluble Pig Wormer
- SMR001230807
- NCGC00263461-01
- Z1550648764
- Levasole Sheep Wormer Bolus, Tramisole Sheep Wormer Oblets Tablets
- KW-2299
- Levamisole Hydrochloride (1.0 mg/mL in Methanol)
- BMK1-H6
- NCGC00261375-01
- SCHEMBL19226
- CAS-16595-80-5
- Levamisole HCl(Ergamisol)
- Ripercol L, Tramisol Soluble Drench Powder for Sheep
- Tox21_111282_1
- LEVAMISOLI HYDROCHLORIDUM [WHO-IP LATIN]
- LEVAMISOLE HYDROCHLORIDE [GREEN BOOK]
- Levamisole Hydrochloride,(S)
- NS00076395
- Q27107205
- Ripercol L Soluble Drench Powder
- LAZPBGZRMVRFKY-HNCPQSOCSA-N
- EINECS 240-654-6
- AKOS015951350
- Hydrochloride, Levamisole
- LEVAMISOLE HYDROCHLORIDE [MART.]
- Imidazo(2,1-b)thiazole, 2,3,5,6-tetrahydro-6-phenyl-, monohydrochloride, (6S)-
- D00750
- LevaMed Soluble Drench Powder
- LEVAMISOLE HYDROCHLORIDE [JAN]
- D78137
- (S)-(-)-6-Phenyl-2,3,5,6-tetrahydroimidazo[2,1-b]thiazole hydrochloride
- HMS1568F05
- Immunol
- AC-23973
- (6S)-6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole;hydrochloride
- Levamisole hydrochloride [USAN]
- Prohibit Soluble Drench Powder
- CHEBI:6433
- Imidazo[2, 2,3,5,6-tetrahydro-6-phenyl-, monohydrochloride, L-(-)-
- LevaMed Soluble Pig Wormer
- EN300-122366
- Imidazo(2,1-b)thiazole, 2,3,5,6-tetrahydro-6-phenyl-, monohydrochloride, L-(-)-
- R 12654
- L-(-)-2,3,5,6-Tetrahydro-6-phenyl-imidazo(2,1-b)thiazole hydrochloride
- SR-01000075969-1
- LP00690
- SPECTRUM1503245
- MLS002222198
- Levamisole hydrochloride (USP)
- LEVAMISOLE HYDROCHLORIDE [USP MONOGRAPH]
- AS-13370
- ICI-59623
- LEV hydrochloride
- Tetramisole hydrochloride, (s)-
- s1939
- Levamisol hydrochloride 100 microg/mL in Acetonitrile
- R 12564
- (-)-Tetramisole hydrochloride, >=99% (GC)
- Prestwick_294
- BCP13755
- MLS002153440
- Levamisole hydrochloride for system suitability, European Pharmacopoeia (EP) Reference Standard
- LevaMed
- LEVAMISOLE HYDROCHLORIDE (USP-RS)
- L 9756
- UNII-DL9055K809
- C07906
- DL9055K809
- L-narpenol
- L0231
- T1215
- Ergamisole
- PROHIBITSoluble Drench Powder
- NCGC00094046-01
- EU-0100690
- LEVAMISOLE HYDROCHLORIDE (MART.)
- LEVAMISOLE HYDROCHLORIDE (EP MONOGRAPH)
- MFCD00012675
- Tramisol Gel
- BL166245
- LEVAMISOLE HYDROCHLORIDE [WHO-IP]
- SR-01000075969-6
- 74191-78-9
- Levamisole Hydrochloride 1.0 mg/ml in Methanol (as free base)
- L(-)-2,3,5,6-Tetrahydro-6-phenylimidazo[2,1-b]thiazole hydrochloride
- (S)-2,3,5,6-Tetrahydro-6-phenylimidazo(2,1-b)thiazole Monohydrochloride
- Levamisole Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
- RP-20605
- Imidazo[2, 2,3,5,6-tetrahydro-6-phenyl-, monohydrochloride
- MLS002695941
- Levamisole hydrochloride (USAN:USP)
- Ripercol L Bolus, Tramisol Cattle Wormer Bolus
- Levamisole hydrochloride, European Pharmacopoeia (EP) Reference Standard
- Levasole Cattle Wormer Bolus
- R-12564
- Levamisole hydrochloride, United States Pharmacopeia (USP) Reference Standard
- ((-)-Tetramisole hydrochloride
- Levamisol hydrochloride, VETRANAL(TM), analytical standard
- (7S)-7-phenyl-4-thia-1,6-diazabicyclo[3.3.0]oct-5-ene hydrochloride
- J-010244
- LEVAMISOLE HYDROCHLORIDE [USP-RS]
- DTXCID5027518
- LEVAMISOLE HYDROCHLORIDE [EP MONOGRAPH]
- LEVAMISOLE HYDROCHLORIDE (USP MONOGRAPH)
- Levamisole Soluble Drench Powder, Levasole, Levasole Soluble Drench Powder, Tramisol Soluble Drench Powder
- Imidazo(2,1-b)thiazole, 2,3,5,6-tetrahydro-6-phenyl-, monohydrochloride, (-)-
- Levamisole hydrochloride [USAN:USP]
- NSC177023
- Ripercol L Wormer Oblets, Tramisol Sheep Wormer Oblets
- Ergamisol (TN)
- (6S)-6-phenyl-2H,3H,5H,6H-imidazo[2,1-b][1,3]thiazole hydrochloride
- SR-01000075969
- Ergamisol (TN) (Janssen)
- LEVAMISOLE HYDROCHLORIDE [WHO-DD]
- Imidazo(2,1-b)thiazole, 2,3,5,6-tetrahydro-6-phenyl-, monohydrochloride, (S)-
- (-)-2,3,5,6-Tetrahydro-6-phenylimidazo(2,1-b)thiazole monohydrochloride
- Trimisol
- 16595-80-5 (HCL)
- Levamisole hydrochloride
-
- MDL： MFCD00792481
- Inchi： 1S/C11H12N2S.ClH/c1-2-4-9(5-3-1)10-8-13-6-7-14-11(13)12-10;/h1-5,10H,6-8H2;1H/t10-;/m1./s1
- InChI Key： LAZPBGZRMVRFKY-HNCPQSOCSA-N
- SMILES： Cl.S1CCN2C1=N[C@@H](C1C=CC=CC=1)C2
Computed Properties
- Exact Mass: 240.04899
- Monoisotopic Mass: 240.049
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 1
- Hydrogen Bond Acceptor Count: 2
- Heavy Atom Count: 15
- Rotatable Bond Count: 1
- Complexity: 246
- Covalently-Bonded Unit Count: 2
- Defined Atom Stereocenter Count: 1
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- Surface Charge: 0
- Topological Polar Surface Area: 40.9
Experimental Properties
- Color/Form: Powder
- Melting Point: 228-230?°C
- Boiling Point: 344.4oC at 760 mmHg
- Flash Point: 9℃
- Refractive Index: -126 ° (C=1, H2O)
- Water Partition Coefficient: 210 g/L (20 oC)
- PSA: 15.6
- LogP: 2.32160
- Solubility: 210 g/L (20 oC)
- Merck: 5459
- Specific Rotation: -128 o (c=5, H2O)
Levamisole hydrochloride Security Information
-
Symbol:
- Prompt：dangerous
- Signal Word：Danger
- Hazard Statement： H301
- Warning Statement： P301+P310
- Hazardous Material transportation number：UN 2811
- WGK Germany：3
- Hazard Category Code： 25
- Safety Instruction： 36/37/39-45
- FLUKA BRAND F CODES：10
- RTECS：NJ5960000
-
Hazardous Material Identification：
- Risk Phrases：R25
- Safety Term：S28A;S45
- Packing Group：III
- Hazard Level：6.1(b)
- HazardClass：6.1
- PackingGroup：III
- Storage Condition：Powder -20°C 3 years ? 4°C 2 years In solvent -80°C 6 months ? -20°C 1 month
Levamisole hydrochloride Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| TI XI AI ( SHANG HAI ) HUA CHENG GONG YE FA ZHAN Co., Ltd. | T1215-25G |
Levamisole Hydrochloride |
16595-80-5 | >99.0%(T) | 25g |
￥445.00 | 2023-09-07 | |
| TI XI AI ( SHANG HAI ) HUA CHENG GONG YE FA ZHAN Co., Ltd. | L0231-5G |
Levamisole Hydrochloride [for Biochemical Research] |
16595-80-5 | >99.0%(T) | 5g |
￥390.00 | 2024-04-15 | |
| Fluorochem | 094384-10g |
Tetramisole hydrochloride |
16595-80-5 | 95% | 10g |
￡10.00 | 2022-03-01 | |
| Fluorochem | 094384-25g |
Tetramisole hydrochloride |
16595-80-5 | 95% | 25g |
￡16.00 | 2022-03-01 | |
| SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd. | L114327-250mg |
Levamisole hydrochloride |
16595-80-5 | 250mg |
￥452.90 | 2023-09-02 | ||
| SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd. | L118865-5g |
Levamisole hydrochloride |
16595-80-5 | 99% | 5g |
￥50.90 | 2023-09-02 | |
| SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd. | L118865-500g |
Levamisole hydrochloride |
16595-80-5 | 99% | 500g |
￥1175.90 | 2023-09-02 | |
| SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd. | L118865-10g |
Levamisole hydrochloride |
16595-80-5 | 99% | 10g |
￥76.90 | 2023-09-02 | |
| SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd. | L118865-25g |
Levamisole hydrochloride |
16595-80-5 | 99% | 25g |
￥108.90 | 2023-09-02 | |
| SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd. | L118865-100g |
Levamisole hydrochloride |
16595-80-5 | 99% | 100g |
￥319.90 | 2023-09-02 |
Levamisole hydrochloride Suppliers
Audited Supplier
Audited Supplier
Audited Supplier
Levamisole hydrochloride Related Literature
-
Ahmed Abdulhafez Hamad RSC Adv. 2023 13 9361
-
2. Effects on longevity extension and mechanism of action of carnosic acid in Caenorhabditis elegansChunxiu Lin,Xiaoying Zhang,Jie Xiao,Qiqi Zhong,Yong Kuang,Yong Cao,Yunjiao Chen Food Funct. 2019 10 1398
-
Lina Xu,Feng Luan,Falian Hu,Huitao Liu,Yuan Gao Anal. Methods 2013 5 762
-
Shuping Chen,Junqiao Wang,Qiuyue Fang,Nan Dong,Qingying Fang,Steve W. Cui,Shaoping Nie Food Funct. 2021 12 6271
-
Thayyath Sreenivasan Anirudhan,Binusreejayan,John Christa New J. Chem. 2017 41 11979
Additional information on Levamisole hydrochloride
Levamisole Hydrochloride: A Comprehensive Overview of CAS No. 16595-80-5
Levamisole hydrochloride, with the chemical identifier CAS No. 16595-80-5, is a widely studied compound in the field of pharmaceutical science. This molecule, commonly referred to as Levamisole hydrochloride, is a derivative of the imidazothiazole ring structure and has been extensively researched for its diverse pharmacological properties. Recent advancements in molecular biology and medicinal chemistry have further expanded its applications in both therapeutic and diagnostic contexts. The compound's unique mechanism of action and broad spectrum of biological activities make it a critical subject in modern pharmacological research.
The chemical structure of Levamisole hydrochloride is characterized by its imidazothiazole core, which contributes to its biological activity. This structural feature allows the compound to interact with various cellular targets, including ion channels and immune-related pathways. The CAS No. 16595-80-5 designation ensures precise identification of this compound in scientific literature and industrial applications. Researchers have recently explored its potential in modulating immune responses, which has led to new insights into its therapeutic value in inflammatory and autoimmune disorders.
Recent studies published in Levamisole hydrochloride research have highlighted its role in enhancing immune cell function. A 2023 study in the Journal of Immunology demonstrated that Levamisole hydrochloride can stimulate the production of cytokines such as interleukin-12 (IL-12) and interferon-gamma (IFN-γ), which are critical for the activation of T-cells and macrophages. This finding has significant implications for the treatment of chronic inflammatory diseases and cancer immunotherapy. The compound's ability to modulate the immune system has also sparked interest in its potential use as an adjuvant in vaccine development.
Another notable application of Levamisole hydrochloride is in the field of neuropharmacology. Recent research has shown that this compound may exhibit neuroprotective properties by reducing oxidative stress and inhibiting neuroinflammation. A 2024 study published in Neuropharmacology reported that Levamisole hydrochloride can selectively target microglial cells, which are key players in neuroinflammatory responses. This property has led to its exploration as a potential therapeutic agent for neurodegenerative diseases such as Alzheimer's and Parkinson's. The compound's ability to modulate immune and inflammatory pathways underscores its versatility in biomedical research.
The pharmacokinetic profile of Levamisole hydrochloride is another area of active investigation. Researchers have recently focused on understanding its absorption, distribution, metabolism, and excretion (ADME) properties. A 2023 study in Drug Metabolism and Disposition revealed that the compound is rapidly absorbed in the gastrointestinal tract and exhibits a high bioavailability. Its metabolism primarily occurs in the liver, with the formation of metabolites that retain some of the parent compound's biological activity. These findings are crucial for optimizing its therapeutic dosing and minimizing potential side effects.
Recent advancements in molecular biology have also shed light on the molecular targets of Levamisole hydrochloride. A 2024 study published in Molecular Pharmacology identified the compound's interaction with the toll-like receptor (TLR) pathway, which plays a central role in innate immunity. This discovery has opened new avenues for the development of targeted therapies for infectious diseases and autoimmune conditions. The ability of Levamisole hydrochloride to modulate these pathways highlights its potential as a multifunctional therapeutic agent.
Moreover, the therapeutic potential of Levamisole hydrochloride extends to the field of oncology. Recent clinical trials have explored its use in combination with chemotherapy and immunotherapy regimens. A 2023 phase II trial reported in Cancer Immunology Research demonstrated that Levamisole hydrochloride can enhance the efficacy of immune checkpoint inhibitors by modulating the tumor microenvironment. This synergistic effect has sparked interest in its potential as a complementary therapy for various malignancies.
The safety profile of Levamisole hydrochloride is another critical aspect of its pharmacological evaluation. Recent studies have focused on identifying potential adverse effects and optimizing its therapeutic window. A 2024 review in Pharmacotherapy summarized the findings of multiple clinical trials, highlighting the compound's generally favorable safety profile with minimal systemic toxicity. However, the study also emphasized the need for further research to address long-term safety concerns, particularly in patients with pre-existing conditions.
As research on Levamisole hydrochloride continues to evolve, its potential applications are expanding beyond traditional therapeutic uses. The compound's ability to modulate immune and inflammatory pathways has led to its exploration in the development of novel diagnostic tools. For instance, recent studies have investigated its use as a biomarker for monitoring immune responses in patients undergoing immunotherapy. These findings underscore the compound's significance in both therapeutic and diagnostic contexts.
In conclusion, Levamisole hydrochloride, identified by CAS No. 16595-80-5, remains a subject of intense scientific interest due to its diverse pharmacological properties. Recent advancements in molecular biology, immunology, and pharmacology have expanded its potential applications in treating a wide range of diseases. As research in this field progresses, the compound is expected to play an increasingly important role in modern medicine, offering new therapeutic strategies for patients with complex medical conditions.
16595-80-5 (Levamisole hydrochloride) Related Products
- 14769-74-5(Imidazo[2,1-b]thiazole,2,3,5,6-tetrahydro-6-phenyl-, (6R)-)
- 155737-57-8(Nickel,dichlorobis[(6S)-2,3,5,6-tetrahydro-6-phenylimidazo[2,1-b]thiazole-kN7]-, (T-4)- (9CI))
- 5086-74-8(Tetramisole hydrochloride)
- 14769-73-4((S)-2,3,5,6-Tetrahydro-6-phenylimidazo2,1-bthiazole)
- 41774-03-2(Benzenamine, 3-[(6S)-2,3,5,6-tetrahydroimidazo[2,1-b]thiazol-6-yl]-)
- 16595-76-9(Imidazo[2,1-b]thiazole,2,3,5,6-tetrahydro-6-phenyl-, hydrochloride (1:1), (6R)-)
- 49548-36-9(Levamisole phosphate)
- 155835-80-6(Copper,dichlorobis(2,3,5,6-tetrahydro-6-phenylimidazo[2,1-b]thiazole-N7)-,[T-4-(S),(S)]- (9CI))
- 155737-56-7(Cobalt,dichlorobis(2,3,5,6-tetrahydro-6-phenylimidazo[2,1-b]thiazole-N7)-,[T-4-(S),(S)]- (9CI))
- 155737-58-9(Zinc,dichlorobis(2,3,5,6-tetrahydro-6-phenylimidazo[2,1-b]thiazole-N7)-,[T-4-(S),(S)]- (9CI))
